Notably, addition of anti-TIGIT to anti-PD-L1 significantly reduced tumor growth and effectuated a trend of increased survival, while PD-L1 blockade by itself did not effectuate a clear survival benefit, possibly due to relatively low expression of PD-L1 in the tumor (Figure S9G). The gene discussed is TIGIT; the disease is neoplasm.